Positions

Overview

  • Dr. Mamie T. Coats obtained her B.S. degree in Biochemistry from Xavier University of Louisiana, New Orleans, Louisiana. She obtained a Ph.D. in Microbiology for the University of Alabama at Birmingham, Birmingham, Alabama. She remained at UAB for her post-doctoral studies.

    Dr. Coats’ research focuses on pneumococcal biofilms and animal models of pneumococcal disease relevant to children.

    Streptococcus pneumoniae remains a major causative agent of community-acquired pneumonia, bacterial meningitis, otitis media and bacteremia worldwide. Children are especially susceptible to pneumococcal infection. While there are pneumococcal vaccines available, the diversity and adaptability of the organism necessitates continued research into its pathogenesis. Our lab focuses on how the presence of biofilms affects the progression of disease and the factors involved in biofilm development. Of particular interest is the role of biofilms in cystic fibrosis and otitis media.

    • Selected Publications

    Academic Article

    Year Title Altmetric
    2021 Uniqueness of rna coliphage qβ display system in directed evolutionary biotechnology.  Viruses.  13. 2021
    2021 Lipopolysaccharide Administration Alters Extracellular Vesicles in Cell Lines and Mice 2021
    2020 A nanovaccine formulation of Chlamydia recombinant MOMP encapsulated in PLGA 85:15 nanoparticles augments CD4+ effector (CD44high CD62Llow) and memory (CD44high CD62Lhigh) T-cells in immunized mice.  Nanomedicine: Nanotechnology, Biology and Medicine.  29. 2020
    2019 Effects of Pseudomonas aeruginosa on microglial-derived extracellular vesicle biogenesis and composition.  Pathogens.  8. 2019
    2018 Hyperencapsulated mucoid pneumococcal isolates from patients with cystic fibrosis have increased biofilm density and persistence in vivo.  Pathogens and Disease.  76. 2018
    2018 Pathogens and their effect on exosome biogenesis and composition.  Biomedicines.  6. 2018
    2018 Function of the RNA coliphage Qβ proteins in medical in vitro evolution 2018
    2017 The anti-microbial peptide TP359 attenuates inflammation in human lung cells infected with Pseudomonas aeruginosa via TLR5 and MAPK pathways.  PLoS ONE.  12. 2017
    2015 The effects of CFTR and mucoid phenotype on susceptibility and innate immune responses in a mouse model of pneumococcal lung disease.  PLoS ONE.  10. 2015
    2014 Silver polyvinyl pyrrolidone nanoparticles exhibit a capsular polysaccharide influenced bactericidal effect against Streptococcus pneumoniae.  Frontiers in Microbiology.  5. 2014
    2012 PspA family distribution, unlike capsular serotype, remains unaltered following introduction of the heptavalent pneumococcal conjugate vaccine 2012
    2011 Exposure of Thomsen-Friedenreich antigen in Streptococcus pneumoniae infection is dependent on pneumococcal neuraminidase A.  Microbial Pathogenesis.  50:343-349. 2011
    2005 Antibodies to the pneumococcal surface protein A, PspA, can be produced in splenectomized mice and can protect splenectomized mice from infection with Streptococcus pneumoniae.  Vaccine.  23:4257-4262. 2005

    Research Overview

  • Dr. Coats research focuses on novel nanomaterial associated formulated treatments of pneumococcal. This involves identifying potential therapeutic targets on Streptococcus pneumoniae, developing and characterizing nanomaterials, and using pulmonary models of infection to assess the potential usefulness of the therapy.

    • Education And Training

  • Doctor of Philosophy in Microbiology, University of Alabama at Birmingham 2005
  • Bachelor of Science or Mathematics in Biochemistry, Xavier University of Louisiana 1997

    • Full Name

  • Mamie Coats